What Polaryx Therapeutics, Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 2 |
| Sells | 0 | 0 |
| Total trades | 0 | 2 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 91,320 |
| Disposed | 0 | 0 |
| Net activity | +0 | +91,320 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Yang Alex Keun Mo | Chief Executive Officer | May 27 | Open-market buy · P | +88,453 | $4.07 | +$360K | 24,233,249 |
| Landis G. Michael | Chief Financial Officer | Feb 18 | Open-market buy · P | +2,867 | $2.79 | +$7.99K | 228,225 |
Loading...
